• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veraxa Biotech AG - Ordinary Shares (NQ:VRXA)

1.870 -0.020 (-1.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 187,972
Open 1.910
Bid (Size) 1.820 (2,000)
Ask (Size) 1.880 (100)
Prev. Close 1.890
Today's Range 1.830 - 1.930
52wk Range 1.700 - 27.36
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market
August 07, 2026
Via Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies
August 05, 2026
Via Investor Brand Network
Topics Intellectual Property

Performance

YTD
-92.5%
-92.5%
1 Month
-8.8%
-8.8%
3 Month
-92.5%
-92.5%
6 Month
-92.5%
-92.5%
1 Year
-92.5%
-92.5%

More News

Read More
VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform
July 29, 2026
Via Investor Brand Network
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms
July 29, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
July 29, 2026
From Veraxa Biotech AG
Via GlobeNewswire
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures
July 27, 2026
Via Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
July 27, 2026
Via Investor Brand Network
News headline image
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
July 27, 2026
From Veraxa Biotech AG
Via GlobeNewswire
News headline image
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
July 24, 2026
From Veraxa Biotech AG
Via GlobeNewswire
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer
July 23, 2026
Via Investor Brand Network
News headline image
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
July 23, 2026
From Veraxa Biotech AG
Via GlobeNewswire
VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany
July 22, 2026
Via Investor Brand Network
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
July 20, 2026
Via Investor Brand Network
News headline image
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
July 20, 2026
From Veraxa Biotech AG
Via GlobeNewswire
Why VERAXA Biotech AG (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D
July 14, 2026
Via Investor Brand Network
Topics Artificial Intelligence
InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development
July 13, 2026
Via Investor Brand Network
Topics Artificial Intelligence
NetworkNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Carl von Halem Interim Chief Financial Officer
July 13, 2026
Via Investor Brand Network
News headline image
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
July 13, 2026
From Veraxa Biotech AG
Via GlobeNewswire
News headline image
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
July 10, 2026
From VERAXA Biotech GmbH
Via GlobeNewswire
VERAXA Biotech AG (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership
July 08, 2026
Via Investor Brand Network
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
July 06, 2026
Via Investor Brand Network
BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
July 06, 2026
Via Investor Brand Network
BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
July 06, 2026
Via Investor Brand Network
News headline image
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
July 06, 2026
From VERAXA Biotech GmbH
Via GlobeNewswire
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
July 02, 2026
Via Investor Brand Network

Frequently Asked Questions

Is Veraxa Biotech AG - Ordinary Shares publicly traded?
Yes, Veraxa Biotech AG - Ordinary Shares is publicly traded.
What exchange does Veraxa Biotech AG - Ordinary Shares trade on?
Veraxa Biotech AG - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Veraxa Biotech AG - Ordinary Shares?
The ticker symbol for Veraxa Biotech AG - Ordinary Shares is VRXA on the Nasdaq Stock Market
What is the current price of Veraxa Biotech AG - Ordinary Shares?
The current price of Veraxa Biotech AG - Ordinary Shares is 1.870
When was Veraxa Biotech AG - Ordinary Shares last traded?
The last trade of Veraxa Biotech AG - Ordinary Shares was at 08/14/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap